50 results on '"Eiermann W"'
Search Results
2. Results from TRIO030, a pre-surgical tissue-acquisition study to evaluate molecular alterations in human breast cancer tissue following short-term exposure to the androgen receptor antagonist darolutamide
3. EMBRACA: Efficacy and safety in comparing talazoparib (TALA) with physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC) and a germline BRCA mutation (gBRCAm); BRCA1/BRCA2 subgroup analysis
4. EMBRACA: Comparison of efficacy and safety of talazoparib (TALA) and physician's choice of therapy (PCT) in patients (pts) with advanced breast cancer (aBC), a germline BRCA1/2 mutation (gBRCAm), and prior platinum treatment
5. Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
6. A pooled analysis of studies evaluating the impact of multi-gene assay testing on adjuvant treatment decisions for women with node-positive breast cancer
7. Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study
8. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial
9. Statistical controversies in clinical research: statistical significance—too much of a good thing …
10. OC-0472: Whole breast radiotherapy does not affect growth of cancer foci in other quadrants: results from the TARGIT Atrial
11. A phase 3 study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with advanced breast cancer (EMBRACA)
12. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
13. Ki67 levels as predictive and prognostic parameters in pretherapeutic breast cancer core biopsies: a translational investigation in the neoadjuvant GeparTrio trial
14. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
15. Meta-Analysis of Prospective European Studies Assessing the Impact of Using The 21-Gene Recurrence Score Assay on Clinical Decision Making in Women With Er-Positive, Her2-Negative Early Stage Breast Cancer
16. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
17. Insights into the Natural History of Subclinical Breast Cancer: A Biological Fall out from the Targit-A Trial
18. Locoregional treatments for triple-negative breast cancer
19. 302 Using the 21-gene Breast Cancer Assay in Adjuvant Decision-making in ER-positive (ER+) Early Breast Cancer (EBC) is Cost-effective: Results of a Large Prospective German Multicenter Study
20. Triple negative breast cancer: Proposals for a pragmatic definition and implications for patient management and trial design
21. PCN55 The Economic Burden of Adjuvant Chemotherapy in Germany
22. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study
23. P206 German multicentre decision impact study of Oncotype DX recurrence score (RS) on adjuvant treatment in estrogen receptor positive (ER+) node negative (N0) and node positive (N+) early breast cancer
24. 101 STRIDE: phase III study of therapeutic cancer vaccine L-BLP25 with hormonal treatment as first-line therapy for women with hormone receptor-positive, inoperable, locally advanced, recurrent, or metastatic breast cancer
25. 5001 CIRG/TORI 010: first analysis of a randomized phase II trial of motesanib plus weekly paclitaxel (P) as first line therapy in HER2-negative metastatic breast cancer (MBC)
26. 0148 REACT study: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients
27. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study
28. Surgical aspect in NOAH Phase III trial (neoadjuvant trastuzumab in HER2-positive locally advanced breast cancer)
29. Hormone-receptor status and likelihood of predicting pathological complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC)
30. Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study
31. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
32. 2030 ORAL Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (NeOAdjuvant Herceptin) Phase III trial
33. O-44 Evaluation of estrogen and progesterone receptor, Her-2 and Topo IIα in primary breast cancer and metastatic axillary lymph nodes
34. 2098 ORAL BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC)
35. Balance of efficacy and toxicity varies with trastuzumab for early breast cancer
36. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
37. PCN23: DISEASE MODELING: DEVELOPING THE INFRASTRUCTURE FOR A COMPREHENSIVE, MULTI-NATIONAL, CLINICAL AND ECONOMIC BREAST CANCER TREATMENT MODEL
38. Results of two open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as Therapy for Advanced Breast Cancer (ABC) in women with tumors over-expressing the HER2-neu proto-oncogene
39. Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT&T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer
40. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: Pivotal trial data
41. PCN9: AN APPROACH TO DESIGNING A MULTINATIONAL MODEL FOR THE CURRENT TREATMENT OF BREAST CANCER
42. GEPARDO — A German trial of preop. chemotherapy with ADoc in breast cancer: first promising results
43. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer *
44. 659 Soluble CD44 standard and V6 in serum of breast cancer patients: An indicator for therapy response
45. 3. A randomized trial of the new specific aromatase inhibitor ‘Arimidex’ (anastrozole) versus megestrol acetate (MA) in the treatment of postmenopausal women with advanced breast cancer (ABC)
46. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer
47. Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy
48. Experiences with SCC antigen, a new tumor marker for cervical carcinoma
49. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma
50. CA-125 in gynecological malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.